IOB - Delayed Quote DKK

Novonesis A/S (0Q4U.IL)

Compare
403.90
-1.85
(-0.46%)
As of 11:11:26 AM GMT. Market Open.
Loading Chart for 0Q4U.IL
DELL
  • Previous Close 405.75
  • Open 409.60
  • Bid 396.90 x --
  • Ask 413.40 x --
  • Day's Range 403.90 - 410.80
  • 52 Week Range 348.40 - 485.60
  • Volume 9,496
  • Avg. Volume 275,427
  • Market Cap (intraday) 111.797B
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) 32.78
  • EPS (TTM) 12.32
  • Earnings Date Feb 26, 2025
  • Forward Dividend & Yield 10.20 (3.59%)
  • Ex-Dividend Date Oct 11, 2023
  • 1y Target Est 411.63

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

www.novozymes.com

6,852

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0Q4U.IL

View More

Performance Overview: 0Q4U.IL

Trailing total returns as of 2/6/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

0Q4U.IL
1.40%
OMX Copenhagen 25 Index
0.37%

1-Year Return

0Q4U.IL
15.56%
OMX Copenhagen 25 Index
4.88%

3-Year Return

0Q4U.IL
1.50%
OMX Copenhagen 25 Index
2.73%

5-Year Return

0Q4U.IL
20.33%
OMX Copenhagen 25 Index
33.04%

Compare To: 0Q4U.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0Q4U.IL

View More

Valuation Measures

As of 2/5/2025
  • Market Cap

    190.15B

  • Enterprise Value

    203.03B

  • Trailing P/E

    58.40

  • Forward P/E

    26.95

  • PEG Ratio (5yr expected)

    0.23

  • Price/Sales (ttm)

    6.53

  • Price/Book (mrq)

    2.30

  • Enterprise Value/Revenue

    8.93

  • Enterprise Value/EBITDA

    57.31

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.31%

  • Return on Assets (ttm)

    10.14%

  • Return on Equity (ttm)

    26.21%

  • Revenue (ttm)

    17.74B

  • Net Income Avi to Common (ttm)

    3.42B

  • Diluted EPS (ttm)

    12.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.05B

  • Total Debt/Equity (mrq)

    58.88%

  • Levered Free Cash Flow (ttm)

    1.02B

Research Analysis: 0Q4U.IL

View More

People Also Watch